TTP LabTech launched a high-throughput option for its Mosquito HT nanolitre liquid-handling system. The Mosquito is designed to pipette through the 50 nl-1.2il volumetric range and produce CVs of less than 10 percent at 50 nl, said UK-based TTP. The HTP version offers increased walk-away time, “making it ideal for sub-cloning plates during compound dissolution in 96-, 384- and 1,536-well plates,” TTP said.
The five-position product can make four copies of a 384-well plate in less than five minutes, or pool four x 384 plates into a 1,536-well plate in less than 12 minutes.
Stratagene rolled out the following products last week: the Brilliant SYBR green single-step quantitative real-time-PCR master mix, which amplifies and detects high- and low-abundance RNA targets from experimental samples like total RNA and synthetic RNA; RNAMaxx high-yield transcription kits, which were designed to produce large amounts of RNA from a variety of DNA template lengths; and the MX3000P real-time quantitative-PCR system, which is dubbed as the first high-performance, low-cost quantitative PCR instrument designed for personal use.
PerkinElmer has launched its DELFIA celiac disease-hybridization assay. The test is suitable for use not only with liquid blood samples but also for blood samples on filter paper, which do not require prior extraction of DNA.
BD Biosciences Clontech has released its BD FACSArray bioanalyzer, a multiparameter platform for bead-based and cellular research. The launch comes on the heels of the release of the company’s PowerScript single shots and BD Sprint PowerScript 96 plate. Each well of BD’s Sprint PowerScript products contains a complete lyophilized master mix of BD PowerScript reverse transcriptase, dNTPs, and buffer, BD said..
Affymetrix has released its new GeneChip CustomSeq SARS pathogen detection-resequencing array. The array, which was designed to enable scientists to resequence different isolates of the coronavirus that causes SARS, resequences the entire 29,700 base pairs in the SARS virus. Affy designed it using sequence data from public health centers in Canada, the United States, and Asia.
The American Association of Blood Banks has given Orchid BioSciences the green light to use SNPs as stand-alone genetic markers in its GeneScreen paternity-testing operations. The SNP-genotyping technology will replace STR techniques, which are considered less cost-effective. Orchid will begin deploying its SNP technology to US paternity-testing labs.